NCT04059484: Phase 2 Study of SAR439859 Versus Physician’s Choice in Premenopausal and Postmenopausal Locally Advanced or Metastatic ER-positive Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received no more than 1 prior chemotherapeutic or 1 targeted therapy regimen for advanced/metastatic disease; Patients must have progressed after at least 6 months of a continuous prior endocrine therapy for advanced breast cancer
Exclusions: Participants with known untreated symptomatic brain metastases that require therapy to control symptoms; Patients with bone-only metastasis; Patients with prior treatment with mTOR inhibitors or any other SERD, except fulvestrant if stopped for at least 3 months before randomization

Comments are closed.

Up ↑